A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease

Chagas disease (ChD), caused by the hemoflagellate parasite Trypanosoma cruzi, affects six to seven million people in Latin America. Lately, it has become an emerging public health concern in nonendemic regions such as North America and Europe. There is no prophylactic or therapeutic vaccine as yet,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:NPJ Vaccines
Main Authors: Portillo, Susana, Zepeda, Brenda G., Iniguez, Eva, Olivas, Janet J., Karimi, Nasim H., Moreira, Otacilio C., Marques, Alexandre F., Michael, Katja, Maldonado, Rosa A., Almeida, Igor C.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6430786/
https://ncbi.nlm.nih.gov/pubmed/30911415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41541-019-0107-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados